AstraZeneca Pharma India Ltd. received a final assessment order from the Income Tax department related to the assessment year 2021-22, involving adjustments on legacy transfer pricing issues totaling around Rs. 14.08 crores, which the company intends to challenge in the Income-tax Appellate Tribunal.